The antibody 34bE12, available from A Menarini Diagnostics, recognises cytokeratin 1, 5, 10 and 14. It reacts with squamous and adenosquamous cell carcinomas, while adenocarcinoma is negative. In normal tissue, 34bE12 stains stratified epithelia, myoepithelial cells and basal cells in the prostate gland and bronchus. Thus, it is useful as a differential marker for squamous carcinoma and adenocarcinoma as well as for benign and malignant tumours of the prostate gland.
Other News
Latest Issues
HORIBA Medical is a renowned specialist in the design and manufacture of automated in-vitro diagnostic systems for analysis in haematology, clinical chemistry, and haemostasis. From compact point of care (POC) solutions to high throughput laboratory systems, HORIBA Medical has successfully developed an array of analysers and data management...
Microbiology Society Annual Conference 2025
Liverpool Arena and Convention Centre
31 March - 3 April, 2025
2nd Global Summit on Pathology
Rome, Italy
10-11 April, 2025
The 10 Year Plan - Clinical Innovations Expo
Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025
Transforming Digital Pathology & AI: The Path Forward
Royal College Of Physicians Of Edinburgh
15 May, 2025
BSMT 40th Anniversary Microbiology Conference
RAF Museum, Hendon, London NW9 5LL
15 May, 2025